Elsevier

The Lancet

Volume 369, Issue 9573, 12–18 May 2007, Pages 1603-1613
The Lancet

Articles
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies

https://doi.org/10.1016/S0140-6736(07)60747-8Get rights and content

Summary

Background

Randomised trials have shown that aspirin reduces the short-term risk of recurrent colorectal adenomas in patients with a history of adenomas or cancer, but large trials have shown no effect in primary prevention of colorectal cancer during 10 years' follow-up. However, the delay from the early development of adenoma to presentation with cancer is at least 10 years. We aimed to assess the longer-term effect of aspirin on the incidence of cancers.

Methods

We studied the effect of aspirin in two large randomised trials with reliable post-trial follow-up for more than 20 years: the British Doctors Aspirin Trial (N=5139, two-thirds allocated 500 mg aspirin for 5 years, a third to open control) and UK-TIA Aspirin Trial (N=2449, two-thirds allocated 300 mg or 1200 mg aspirin for 1–7 years, a third placebo control). We also did a systematic review of all relevant observational studies to establish whether associations were consistent with the results of the randomised trials and, if so, what could be concluded about the likely effects of dose and regularity of aspirin use, other non-steroidal anti-inflammatory drugs (NSAID), and the effect of patient characteristics.

Results

In the randomised trials, allocation to aspirin reduced the incidence of colorectal cancer (pooled HR 0·74, 95% CI 0·56–0·97, p=0·02 overall; 0·63, 0·47–0·85, p=0·002 if allocated aspirin for 5 years or more). However, this effect was only seen after a latency of 10 years (years 0–9: 0·92, 0·56–1·49, p=0·73; years 10–19: 0·60, 0·42–0·87, p=0·007), was dependent on duration of scheduled trial treatment and compliance, and was greatest 10–14 years after randomisation in patients who had had scheduled trial treatment of 5 years or more (0·37, 0·20–0·70, p=0·002; 0·26, 0·12–0·56, p=0·0002, if compliant). No significant effect on incidence of non-colorectal cancers was recorded (1.01, 0.88–1.16, p=0.87). In 19 case-control studies (20 815 cases) and 11 cohort studies (1 136 110 individuals), regular use of aspirin or NSAID was consistently associated with a reduced risk of colorectal cancer, especially after use for 10 years or more, with no difference between aspirin and other NSAIDs, or in relation to age, sex, race, or family history, site or aggressiveness of cancer, or any reduction in apparent effect with use for 20 years or more. However, a consistent association was only seen with use of 300 mg or more of aspirin a day, with diminished and inconsistent results for lower or less frequent doses.

Interpretation

Use of 300 mg or more of aspirin a day for about 5 years is effective in primary prevention of colorectal cancer in randomised controlled trials, with a latency of about 10 years, which is consistent with findings from observational studies. Long-term follow-up is required from other randomised trials to establish the effects of lower or less frequent doses of aspirin.

Introduction

Colorectal cancer is the second most common cancer in developed countries, with a lifetime risk of 5%, and about 1 million new cases worldwide every year.1 Most colorectal cancers develop from adenomas (the so-called adenoma-carcinoma sequence1, 2), and several randomised trials have shown that aspirin3, 4, 5 and cyclo-oxygenase-2 enzyme (COX-2) inhibitors6, 7, 8 reduce the recurrence of adenomas by about 40% in patients with previous adenomas or colorectal cancer. However, these trials had only 2–3 years follow-up and were therefore unable to establish any effect of aspirin or COX-2 inhibitors on colorectal cancer. The likelihood of malignant transformation of adenomas that develop despite aspirin or COX-2 inhibitors versus those that are prevented is uncertain. However, such information is important because, although up to 40% of people in developed countries have one or more colorectal adenomas by age 60 years, less than 10% of these adenomas progress to cancer.9 Moreover, the secondary prevention of adenomas by short-term treatment with aspirin or COX-2 inhibitors cannot be assumed to be maintained on long-term treatment, nor can we assume that the same effect would be seen in primary prevention. Indeed, no effect of aspirin on diagnosis of colonic adenomas (2510 vs 2578, relative risk 0·97, 95% CI 0·92–1·02) was reported during an average of 10 years follow-up in the Women's Health Study randomised trial of low dose aspirin versus placebo.10

Long-term use of COX-2 inhibitors is not recommended because of adverse effects on vascular risk,11, 12 but long-term treatment with aspirin is feasible in patients with or without vascular disease.13, 14 Aspirin has been shown to reduce experimentally-induced colonic malignancies in animals,2 and some observational studies have reported a reduced incidence of colorectal cancers in regular users of aspirin (or non-steroidal anti-inflammatory drugs [NSAID]),15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 although there is substantial heterogeneity in apparent effect between studies,61, 62 and the two most recent large cohort studies reported no effect.46, 59 Experience with other observational risk associations has highlighted the need for randomised trials in proving causation,63, 64 and two large trials of aspirin in primary prevention showed no effect on colorectal cancer during 10 years of follow-up.10, 65 However, a latency of more than 10 years would be expected, considering that the delay between the initiation of development of an adenoma, the point at which aspirin is believed to act,9 and presentation of colorectal cancer is estimated to be 10–15 years.66, 67

We therefore studied the effects of aspirin on the subsequent incidence of colorectal cancers in two large randomised trials of aspirin versus no aspirin in which reliable post-trial follow-up data of more than 20 years were available. We also did a systematic review of relevant observational studies to assess whether, with appropriate stratification by duration and extent of exposure, findings for colorectal cancer were consistent with the randomised studies and, if so, what additional conclusions could be drawn about the likely effects of dose and regularity of aspirin, other NSAID, long-term continuous treatment, and the effect of age, sex, race, and family history, and site or aggressiveness of cancer.

Section snippets

Randomised trials

Two randomised trials of aspirin versus no aspirin began in the UK around 1980: the British Doctors Aspirin Trial68 and the UK Transient Ischaemic Attack Aspirin Trial (UK-TIA trial).69 The methods and results of these trials have been published previously.68, 69 Sustained long-term post-trial follow-up was available for all cancers via the UK National Cancer Registry. Our follow-up study was approved by our institutional research ethics committee.

In the British Doctors Aspirin Trial, 5139 male

Randomised trials

5139 individuals (mean [SD] age 61·6 [7·0] years; 31% smokers) were randomised in the British Doctors Aspirin Trial and 2449 (mean [SD] age 60·3 [9·0] years; 73% male, 53% smokers) in the UK-TIA trial. All recruits to the British Doctors Aspirin Trial were treated for 5–6 years (mean 5·7, SD 0·89) and 99% of survivors completed a final questionnaire at the end of scheduled follow up in 1984.68 Patients in the UK-TIA trial were treated for 1–7 years and all were accounted for at the end of the

Discussion

The randomised studies provide good evidence that at least 300 mg aspirin a day for about 5 years is effective in the primary prevention of colorectal cancer, with a 10-year latency of effect that is consistent with the apparent effects in the observational studies and with our understanding of the adenoma-carcinoma sequence.1, 9, 66, 67 The greater effect of aspirin allocation on incidence of colorectal cancer in the double-blind placebo controlled UK-TIA trial than in the open-label British

References (84)

  • DA Lawlor et al.

    Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?

    Lancet

    (2004)
  • DH Brewster et al.

    Reliability of cancer registration data in Scotland, 1997

    Eur J Cancer

    (2002)
  • D Brewster et al.

    Registration of colorectal cancer in Scotland: an assessment of data accuracy based on review of medical records

    Public Health

    (1995)
  • CE Eberhart et al.

    Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

    Gastroenterology

    (1994)
  • BS Reddy et al.

    Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats

    Carcinogenesis

    (1993)
  • JA Baron et al.

    A randomized trial of aspirin to prevent colorectal adenomas

    N Engl J Med

    (2003)
  • RS Sandler et al.

    A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

    N Engl J Med

    (2003)
  • MM Bertagnolli et al.

    Celecoxib for the prevention of sporadic colorectal adenomas

    N Engl J Med

    (2006)
  • N Arber et al.

    Celecoxib for the prevention of colorectal adenomatous polyps

    N Engl J Med

    (2006)
  • JS Levine et al.

    Adenomatous polyps of the colon

    N Engl J Med

    (2006)
  • NR Cook et al.

    Low-dose aspirin in the primary prevention of cancer (The Women's Health Study): a randomized controlled trial

    JAMA

    (2005)
  • SD Solomon et al.

    Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

    Circulation

    (2006)
  • RS Bresalier et al.

    Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

    N Engl J Med

    (2005)
  • Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

    BMJ

    (2002)
  • JS Berger et al.

    Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

    JAMA

    (2006)
  • NJ Camp et al.

    Classification tree analysis: a statistical tool to investigate risk factor interactions with an example for colon cancer (United States)

    Cancer Causes Control

    (2002)
  • VM Chia et al.

    Risk of microsatellite-unstable colorectal cancer is associated jointly with smoking and nonsteroidal anti-inflammatory drug use

    Cancer Res

    (2006)
  • JP Collet et al.

    Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing

    Br J Cancer

    (1999)
  • PF Coogan et al.

    NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease

    Cancer Causes Control

    (2000)
  • GD Friedman et al.

    Drugs and colon cancer

    Pharmacoepidemiol Drug Saf

    (1998)
  • X Gao et al.

    Nonsteroidal anti-inflammatory drugs and the risk of polyposis, colonal carcinoma and rectal carcinoma

    Chin J Prev Med

    (2002)
  • LA Garcia-Rodriguez et al.

    Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs

    Epidemiology

    (2001)
  • M Juarranz et al.

    Physical exercise, use of Plantago ovata and aspirin, and reduced risk of colon cancer

    Eur J Cancer Prev

    (2002)
  • GA Kune et al.

    Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study

    Cancer Res

    (1988)
  • C La Vecchia et al.

    Aspirin and colorectal cancer

    Br J Cancer

    (1997)
  • MJ Langman et al.

    Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database

    BMJ

    (2000)
  • CR Meier et al.

    Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer

    Pharmacotherapy

    (2002)
  • JE Muscat et al.

    Nonsteroidal antiinflammatory drugs and colorectal cancer

    Cancer

    (1994)
  • AI Neugut et al.

    Association between coronary heart disease and cancers of the breast, prostate, and colon

    Cancer Epidemiol Biomarkers Prev

    (1998)
  • II Peleg et al.

    Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer

    Arch Intern Med

    (1994)
  • II Peleg et al.

    Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia

    Dig Dis Sci

    (1996)
  • MJ Reeves et al.

    Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women

    Cancer Epidemiol Biomarkers Prev

    (1996)
  • Cited by (0)

    View full text